Key result
Acute rosiglitazone improves FMD by ~29% vs vehicle in senescent nonhuman primates.
Why the study?
The age effects on non-invasive measurements of FMD and PWV and the relationship of EMPs/EPCs with FMD in non-human primates were unknown, limiting translational drug discovery.
Does rosiglitazone or nicotine alter flow-mediated dilation in senescent non-human primates?
Does rosiglitazone or nicotine alter flow-mediated dilation in senescent non-human primates?
Non-invasive FMD and PWV in non-human primates correlate with age and respond to pharmacological interventions, validating this model for translational vascular research.
Answers are grounded in this paper and cite their sources.
Supports rosiglitazone effects on endothelial function in aging models; leaves open translation to human senescent populations.
BACKGROUND: Endothelium-dependent flow mediated dilation (FMD) and pulse-wave velocity (PWV), are used as measures of vascular health and predictors of cardiovascular risk in clinical studies, and both are age-dependent. Numbers of circulating endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are also associated with cardiovascular risk, but independent of age in humans. The use of these measurements for pre-clinical assessment of drug cardiovascular safety and efficacy in non-human primates (NHPs) may promote the translation of drug-induced effects on vascular function to clinic outcomes. However, in NHPs, the age effects on the non-invasive measurements of FMD and PWV and the relationship of EMPs/EPCs with FMD are unknown. METHODS: A non-invasive, clinically-relevant approach to assess FMD and PWV was used to examine their relationship with age and with EMPs/EPCs in NHPs. The effects on FMD of nicotine and rosiglitazone were evaluated in senescent primates in an effort to validate our FMD method for pre-clinical assessment of vascular function. RESULTS: FMD and PWV methods were established in a colony (n = 25) of metabolically healthy, cynomolgus monkeys ranging in age from 6 to 26 years. FMD, defined as the percent change, at 1 min of cuff release, from baseline vascular diameter (0.15 ± 0.03 cm), had a strong, negative correlation with age (r = -0.892, p < 0.0001), ranging from 6% to 33%. PWV positively correlated with age (r = 0.622, p < 0.002) in the same healthy monkeys. Nicotine and rosiglitazone, were evaluated in subsets of senescent primates (mean age 16.3 ± 1.5[SEM] years). Rosiglitazone significantly improved FMD (21.0 ± 1.6% vs. vehicle 16.3 ± 1.6%, p < 0.01) without changing baseline diameters, and coincided with a significant increase in circulating numbers of endothelial progenitor cells (CD45-CD31 + CD34 + VEGFR2+ 7.1 ± 1.3 vs. 4.8 ± 1.1 counts/μl) and a decrease in endothelial microparticles (CD45-CD42a-CD54+ 26.7 ± 11.1 vs. 62.2 ± 9.8 counts/μl)(p < 0.05). Conversely, FMD was significantly reduced with nicotine (8.7 ± 1.4% vs. vehicle 20.1 ± 2.2%, p < 0.05). CONCLUSIONS: Adult NHPs demonstrate the characteristic linear relationship between age and vascular function using the non-invasive clinically-related measurements of FMD and PWV. However, numbers of circulating EMPs and EPCs did not correlate with age. Endothelial function assessed with FMD, together with EMPs/EPCs assessment, may serve as a novel approach for translational research and therapeutic discovery. Age should be considered in the study design or data analyses when FMD or PWV is used in NHPs.
No takes yet. Share an insight, caveat, or question.
Knight et al. (2013) studied Healthy (n=25). Rosiglitazone vs. Vehicle was evaluated on Flow-mediated dilation (FMD) (p=<0.01). Acute treatment with rosiglitazone significantly improved flow-mediated dilation (21.0% vs. 16.3% with vehicle) in senescent nonhuman primates without changing baseline diameters.
Synapse has enriched 10 related papers. Consider them for comparative context: